Andrew J. Schwab
CIK 1598549 · Co-CEO · last filed 2026-06-12
Andrew J. Schwab is a Co-CEO who has filed 38 SEC Form 4 insider transactions across 15 companies since 2014. The most recent filing, for CAMP, was dated Jun 12, 2026. Across all open-market trades the lifetime net is −$176.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $151.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$151.57M
15
38
-$175.95M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | 302,770 | $3.42 | $1.04M | $10.00M | 4 | 2026-06-12 |
| SKYE | Director | 1,621,043 | $0.61 | $996.8K | -$2.55M | 6 | 2026-04-02 |
| ARTV | 10%+ Owner | 1,182,054 | $10.53 | $12.45M | $60.00M | 1 | 2024-07-24 |
| IMRA | Director | 3,888,992 | $14.49 | $56.35M | -$45.00M | 3 | 2024-02-02 |
| Pear Therapeutics, Inc. (PEARW) Delisted | Director | 12,989,936 | $0.01 | $76.6K | -$8.38M | 2 | 2022-09-16 |
| RLYB | 10%+ Owner | 162,760 | $16.16 | $2.63M | -$7.80M | 1 | 2022-05-25 |
| IPI Legacy Liquidation Co (IMPL) Delisted | 10%+ Owner | 1,849,456 | $0.24 | $445.9K | $60.38M | 1 | 2021-04-29 |
| CABA | 10%+ Owner | 380,218 | $2.73 | $1.04M | -$35.22M | 1 | 2021-01-12 |
| 5:01 Acquisition Corp. (FVAM) Delisted | Co-CEO | 365,126 | $10.00 | $3.65M | $0 | 4 | 2020-12-01 |
| scPharmaceuticals Inc. (SCPH) Delisted | 10%+ Owner | 3,123,303 | $5.67 | $17.71M | $5.00M | 1 | 2020-05-28 |
| ARVN | 10%+ Owner | 3,888,216 | $8.20 | $31.88M | -$106.29M | 2 | 2019-07-01 |
| CRNX | 94,489 | $83.86 | $7.92M | -$33.30M | 1 | 2019-06-25 | |
| Q32 Bio Inc. (FIXX) Delisted | 10%+ Owner | 1,367 | $16.82 | $23.0K | -$82.79M | 2 | 2019-05-20 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | 10%+ Owner | 65,699 | — | — | $10.00M | 1 | 2015-02-06 |
| FLXN | Director | 1,512,076 | $24.65 | $37.27M | $0 | 2 | 2014-03-04 |
Recent Filings
38 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | CAMP | Grant (A) | — | $0 | EDGAR |
| 2026-04-02 | SKYE | Grant (A) | — | $0 | EDGAR |
| 2026-02-09 | SKYE | Grant (A) | — | $0 | EDGAR |
| 2025-09-15 | CAMP | Grant (A) | +2,941,176 | $4.50M | EDGAR |
| 2025-08-22 | SKYE | Sell (S) | −231,405 | -$800.5K | EDGAR |
| 2025-06-27 | CAMP | Grant (A) | — | $0 | EDGAR |
| 2025-02-26 | SKYE | Grant (A) | — | $0 | EDGAR |
| 2024-10-30 | SKYE | Grant (A) | — | $0 | EDGAR |
| 2024-10-15 | CAMP | Mixed | +2,927,915 | $10.00M | EDGAR |
| 2024-09-13 | SKYE | Sell (S) | −266,337 | -$1.75M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.